Craig I Coleman1, Sylvia Haas2, Alexander G G Turpie3, Silvia Kuhls4, Susanne Hess5, Thomas Evers6, Pierre Amarenco7, Paulus Kirchhof8,9, A John Camm10. 1. Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, Connecticut. craig.coleman@hhchealth.org. 2. Vascular Center, Munich, Germany. 3. Department of Medicine, McMaster University, Hamilton, Ontario, Canada. 4. Global Integrated Analysis, Bayer Pharma AG, Wuppertal, Germany. 5. Global Medical Affairs, Bayer Pharma AG, Berlin, Germany. 6. Global Market Access, Bayer Pharma AG, Berlin, Germany. 7. Department of Neurology and Stroke Center, Paris-Diderot-Sorbonne University, Paris, France. 8. Centre for Cardiovascular Sciences, University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom. 9. Department of Cardiovascular Medicine, University of Münster, Münster, Germany. 10. Cardiovascular and Cell Sciences Research Institute, St George's, University of London, London, United Kingdom.
Abstract
BACKGROUND: The efficacy, safety, and ease of use of rivaroxaban may reduce anticoagulation-treatment burden and improve nonvalvular atrial fibrillation (NVAF) patient satisfaction compared with vitamin K antagonists (VKAs). HYPOTHESIS: Transitioning from a VKA to rivaroxaban improves treatment satisfaction in routine practice. METHODS: Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation (XANTUS) is a prospective, noninterventional study in patients with NVAF prescribed rivaroxaban for prevention of stroke in routine practice. Patients receiving a VKA 4 weeks prior to the initial XANTUS study visit and switched to rivaroxaban were asked to complete the Anti-Clot Treatment Scale (ACTS). Changes from the initial visit to the first follow-up visit at ∼ 3 months (corresponding to a comparison of rivaroxaban vs prior VKA) for ACTS burden and benefit scores were calculated using and reported as least squared mean differences (LSMDs) with 95% confidence intervals (CIs). RESULTS: The study included 1291 NVAF patients with prior VKA treatment. The mean baseline ACTS burden and benefit scores were 50.51 ± 8.42 and 10.30 ± 2.70, respectively. After ∼ 3 months of rivaroxaban treatment, LSMDs were 4.38 points (95% CI: 2.53-6.22, P < 0.0001) for the burden and 1.01 points (95% CI: 0.27-1.75, P = 0.0075) for the benefit score. Fifty-four percent and 48% of patients reported experiencing at least a minimally important clinical difference in burden and benefit scores, respectively. CONCLUSIONS: Within this XANTUS cohort, switching from a VKA to rivaroxaban yielded statistically and clinically significant improvements in ACT burden and benefit scores.
BACKGROUND: The efficacy, safety, and ease of use of rivaroxaban may reduce anticoagulation-treatment burden and improve nonvalvular atrial fibrillation (NVAF) patient satisfaction compared with vitamin K antagonists (VKAs). HYPOTHESIS: Transitioning from a VKA to rivaroxaban improves treatment satisfaction in routine practice. METHODS: Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation (XANTUS) is a prospective, noninterventional study in patients with NVAF prescribed rivaroxaban for prevention of stroke in routine practice. Patients receiving a VKA 4 weeks prior to the initial XANTUS study visit and switched to rivaroxaban were asked to complete the Anti-Clot Treatment Scale (ACTS). Changes from the initial visit to the first follow-up visit at ∼ 3 months (corresponding to a comparison of rivaroxaban vs prior VKA) for ACTS burden and benefit scores were calculated using and reported as least squared mean differences (LSMDs) with 95% confidence intervals (CIs). RESULTS: The study included 1291 NVAF patients with prior VKA treatment. The mean baseline ACTS burden and benefit scores were 50.51 ± 8.42 and 10.30 ± 2.70, respectively. After ∼ 3 months of rivaroxaban treatment, LSMDs were 4.38 points (95% CI: 2.53-6.22, P < 0.0001) for the burden and 1.01 points (95% CI: 0.27-1.75, P = 0.0075) for the benefit score. Fifty-four percent and 48% of patients reported experiencing at least a minimally important clinical difference in burden and benefit scores, respectively. CONCLUSIONS: Within this XANTUS cohort, switching from a VKA to rivaroxaban yielded statistically and clinically significant improvements in ACT burden and benefit scores.
Authors: Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf Journal: N Engl J Med Date: 2011-08-10 Impact factor: 91.245
Authors: Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Craig I Coleman; Matthew S Roberts; Diana M Sobieraj; Soyon Lee; Tawfikul Alam; Rajbir Kaur Journal: Curr Med Res Opin Date: 2012-04-05 Impact factor: 2.580
Authors: Craig I Coleman; Stacey M Coleman; Julie Vanderpoel; Winnie Nelson; Jennifer A Colby; Jennifer M Scholle; Jeffrey Kluger Journal: J Investig Med Date: 2013-06 Impact factor: 2.895
Authors: Luke Bamber; Maria Y Wang; Martin H Prins; Cathleen Ciniglio; Rupert Bauersachs; Anthonie W A Lensing; Stefan J Cano Journal: Thromb Haemost Date: 2013-07-11 Impact factor: 5.249
Authors: Ajay K Kakkar; Iris Mueller; Jean-Pierre Bassand; David A Fitzmaurice; Samuel Z Goldhaber; Shinya Goto; Sylvia Haas; Werner Hacke; Gregory Y H Lip; Lorenzo G Mantovani; Alexander G G Turpie; Martin van Eickels; Frank Misselwitz; Sophie Rushton-Smith; Gloria Kayani; Peter Wilkinson; Freek W A Verheugt Journal: PLoS One Date: 2013-05-21 Impact factor: 3.240
Authors: Weijia Wang; Jane Saczynski; Darleen Lessard; Tanya Mailhot; Bruce Barton; Molly E Waring; Felix Sogade; Robert Hayward; Robert Helm; David D McManus Journal: J Cardiovasc Electrophysiol Date: 2019-09-25
Authors: Carmen Suárez Fernández; Luis Castilla-Guerra; Jesus Cantero Hinojosa; Josep Maria Suriñach; Fernando Acosta de Bilbao; Juan José Tamarit; José Luis Diaz Diaz; Jose Luis Hernandez; Antonio Pose; Manuel Montero-Pérez-Barquero; Jaume Roquer; Jaime Gállego; José Vivancos; Jose María Mostaza Journal: Patient Prefer Adherence Date: 2018-02-19 Impact factor: 2.711
Authors: Alexander C Perino; Peter Shrader; Mintu P Turakhia; Jack E Ansell; Bernard J Gersh; Gregg C Fonarow; Alan S Go; Daniel W Kaiser; Elaine M Hylek; Peter R Kowey; Daniel E Singer; Laine Thomas; Benjamin A Steinberg; Eric D Peterson; Jonathan P Piccini; Kenneth W Mahaffey Journal: J Am Heart Assoc Date: 2019-05-07 Impact factor: 5.501
Authors: Leo Ungar; Fatima Rodriguez; Anne S Hellkamp; Richard C Becker; Scott D Berkowitz; Guenter Breithardt; Keith A A Fox; Werner Hacke; Jonathan L Halperin; Graeme J Hankey; Christopher C Nessel; Daniel E Singer; Manesh R Patel; Jonathan P Piccini; Kenneth W Mahaffey Journal: Cardiol Ther Date: 2019-08-02